These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 22658702)

  • 1. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.
    Moreau C; Delval A; Defebvre L; Dujardin K; Duhamel A; Petyt G; Vuillaume I; Corvol JC; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Sablonniere B; Azulay JP; Tison F; Rascol O; Vidailhet M; Destée A; Bloem BR; Bordet R; Devos D;
    Lancet Neurol; 2012 Jul; 11(7):589-96. PubMed ID: 22658702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate for freezing of gait in Parkinson's disease.
    Rodriguez-Oroz MC
    Lancet Neurol; 2012 Jul; 11(7):569-70. PubMed ID: 22710750
    [No Abstract]   [Full Text] [Related]  

  • 3. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.
    Lhommée E; Wojtecki L; Czernecki V; Witt K; Maier F; Tonder L; Timmermann L; Hälbig TD; Pineau F; Durif F; Witjas T; Pinsker M; Mehdorn M; Sixel-Döring F; Kupsch A; Krüger R; Elben S; Chabardès S; Thobois S; Brefel-Courbon C; Ory-Magne F; Regis JM; Maltête D; Sauvaget A; Rau J; Schnitzler A; Schüpbach M; Schade-Brittinger C; Deuschl G; Houeto JL; Krack P;
    Lancet Neurol; 2018 Mar; 17(3):223-231. PubMed ID: 29452685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study.
    Vitek JL; Jain R; Chen L; Tröster AI; Schrock LE; House PA; Giroux ML; Hebb AO; Farris SM; Whiting DM; Leichliter TA; Ostrem JL; San Luciano M; Galifianakis N; Verhagen Metman L; Sani S; Karl JA; Siddiqui MS; Tatter SB; Ul Haq I; Machado AG; Gostkowski M; Tagliati M; Mamelak AN; Okun MS; Foote KD; Moguel-Cobos G; Ponce FA; Pahwa R; Nazzaro JM; Buetefisch CM; Gross RE; Luca CC; Jagid JR; Revuelta GJ; Takacs I; Pourfar MH; Mogilner AY; Duker AP; Mandybur GT; Rosenow JM; Cooper SE; Park MC; Khandhar SM; Sedrak M; Phibbs FT; Pilitsis JG; Uitti RJ; Starr PA
    Lancet Neurol; 2020 Jun; 19(6):491-501. PubMed ID: 32470421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous low-frequency deep brain stimulation of the substantia nigra pars reticulata and high-frequency stimulation of the subthalamic nucleus to treat levodopa unresponsive freezing of gait in Parkinson's disease: A pilot study.
    Valldeoriola F; Muñoz E; Rumià J; Roldán P; Cámara A; Compta Y; Martí MJ; Tolosa E
    Parkinsonism Relat Disord; 2019 Mar; 60():153-157. PubMed ID: 30241951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
    Devos D; Krystkowiak P; Clement F; Dujardin K; Cottencin O; Waucquier N; Ajebbar K; Thielemans B; Kroumova M; Duhamel A; Destée A; Bordet R; Defebvre L
    J Neurol Neurosurg Psychiatry; 2007 May; 78(5):470-5. PubMed ID: 17098845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gait and attentional performance in freezers under methylphenidate.
    Delval A; Moreau C; Bleuse S; Guehl D; Bestaven E; Guillaud E; Dujardin K; Defebvre L; Devos D
    Gait Posture; 2015 Feb; 41(2):384-8. PubMed ID: 25468682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial.
    Okun MS; Gallo BV; Mandybur G; Jagid J; Foote KD; Revilla FJ; Alterman R; Jankovic J; Simpson R; Junn F; Verhagen L; Arle JE; Ford B; Goodman RR; Stewart RM; Horn S; Baltuch GH; Kopell BH; Marshall F; Peichel D; Pahwa R; Lyons KE; Tröster AI; Vitek JL; Tagliati M;
    Lancet Neurol; 2012 Feb; 11(2):140-9. PubMed ID: 22239915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease.
    Ferraye MU; Debû B; Fraix V; Goetz L; Ardouin C; Yelnik J; Henry-Lagrange C; Seigneuret E; Piallat B; Krack P; Le Bas JF; Benabid AL; Chabardès S; Pollak P
    Brain; 2010 Jan; 133(Pt 1):205-14. PubMed ID: 19773356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacological options for treating advanced Parkinson's disease.
    Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
    Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nigral stimulation for resistant axial motor impairment in Parkinson's disease? A randomized controlled trial.
    Weiss D; Walach M; Meisner C; Fritz M; Scholten M; Breit S; Plewnia C; Bender B; Gharabaghi A; Wächter T; Krüger R
    Brain; 2013 Jul; 136(Pt 7):2098-108. PubMed ID: 23757762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease: a prospective controlled study.
    Vercruysse S; Vandenberghe W; Münks L; Nuttin B; Devos H; Nieuwboer A
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):871-7. PubMed ID: 24396010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
    Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial.
    Odekerken VJ; van Laar T; Staal MJ; Mosch A; Hoffmann CF; Nijssen PC; Beute GN; van Vugt JP; Lenders MW; Contarino MF; Mink MS; Bour LJ; van den Munckhof P; Schmand BA; de Haan RJ; Schuurman PR; de Bie RM
    Lancet Neurol; 2013 Jan; 12(1):37-44. PubMed ID: 23168021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.